Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, May 28, 2013

Introduction
I have started to write a newsletter on a weekly or bi-weekly basis to supplement my reports and blogs. In…
Read more…

SmithOnStocks Opines on Stocks May 19, Edition

One Approach for Investing in Emerging Biotechnology Stocks
I write on biotechnology and pharmaceutical companies of all sizes, but I have…
Read more…

A.P. Pharma: Management Change is a Positive for the Stock (APPA.OB, $0.39)

Introduction
This report deals with the just announced management change at A.P. Pharma (APPA.OB) and the positive impact that I believe…
Read more…

A.P. Pharma Receives Complete Response Letter on APF530 (APPA.OB, $0.34)

Overview
A.P. Pharma has just released the disappointing news that it has received a Complete Response Letter for APF530. The press…
Read more…

A.P. Pharma: PDUFA Date on APF530 Looms and I Am a Buyer (APPA.OB, $0.70)

Investment Opinion and Background
I initiated coverage of A.P. Pharma (APPA.OB) in April of 2012 with a Buy. I am anticipating…
Read more…

A.P. Pharma: Refiling of NDA for APF530 Could Lead to Stock Price Strength

Catalyst
AP Pharma (APPA.OB) announced that it has resubmitted its New Drug Application (NDA) to the FDA for its lead product…
Read more…

Recently Added Board Member Brings Great Expertise to the Potential Launch of APF530 (APPA, $0.64)

Investment Thesis and Price Target
I initiated coverage of A.P. Pharma (APPA.OB) with a buy at $0.42 per share on April…
Read more…

Stock Weakness Following Equity Offering Provides A Buying Opportunity in A.P. Pharma (APPA, $0.58)

Investment Thesis

The equity offering by A.P. Pharma of 102 million shares at $0.52 per share has put pressure on the…
Read more…

A.P. Pharma: Ondansetron's Link to QT Interval Prolongation is a Huge Positive for APF530

The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to…
Read more…

A.P. Pharma: Ondansetronís Link to QT Interval Prolongation is a Huge Positive for APF530 (APPA, $0.68)

Investment Thesis
The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran)…
Read more…

Initiating Coverage of A.P. Pharma with a Buy (APPA, $0.42)

I have just published a report initiating coverage on A.P. Pharma (APPA, $0.42) in which I recommend purchase; my 2015…
Read more…

A.P. Pharma: Initiating Coverage with a Buy (APPA.OB, $0.42)

Key Investment Conclusions
In this report, I have made projections for sales, earnings and cash flow for A.P. Pharma (APPA.OB) through…
Read more…